Rui Monteiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rui Monteiro has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
- Christine Lindsay Mummery
Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands
13 shared publications - Roger Patient
University of Oxford
10 shared publications - Tomasz Dobrzycki
Immunocore Ltd., Abingdon, USA
8 shared publications Roger Patient
MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
6 shared publicationsSusana M. Chuva de Sousa Lopes
Department of Anatomy and Embryology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
6 shared publicationsChristopher B. Mahony
Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
4 shared publications
Latest Publications
- Open Access
Dll4 and Jag1a signalling act sequentially and cooperatively to drive hematopoietic stem cell fate specification
Hematopoietic stem and progenitor cells (HSPCs) arise from a specialized subset of arterial endothelial cells, the hemogenic endothelium (HE), during embryonic development and sustain blood production throughout life. Notch signalling is a key regulator of this process: its ligand Jag1 promotes HSPC formation, whereas Dll4 promotes arterial identity. However, how the activities of these ligands are temporally coordinated during HSPC emergence remains unresolved. Here we demonstrate that Dll4 is required prior to circulation onset, acting by dampening MAPK signalling to drive the transition from pre-HE to HE fate and enabling HE differentiation towards HSPCs. Subsequently, after circulation starts, Jag1a acts to maintain gene expression in HE and support transition to HSPC fate. Jag1a activity depends on blood flow-induced shear stress and rescues HSPC loss caused by impaired flow. Thus, rather than playing opposing roles, Dll4 and Jag1a act sequentially and coordinately to drive the endothelial-to-hematopoietic transition and promote HSPC emergence.
Open AccessDll4 and Jag1a signalling act sequentially and cooperatively to drive hematopoietic stem cell fate specification
Hematopoietic stem and progenitor cells (HSPCs) arise from a specialized subset of arterial endothelial cells, the hemogenic endothelium (HE), during embryonic development and sustain blood production throughout life. Notch signalling is a key regulator of this process: its ligand Jag1 promotes HSPC formation, whereas Dll4 promotes arterial identity. However, how the activities of these ligands are temporally coordinated during HSPC emergence remains unresolved. Here we demonstrate that Dll4 is required prior to circulation onset, acting by dampening MAPK signalling to drive the transition from pre-HE to HE fate and enabling HE differentiation towards HSPCs. Subsequently, after circulation starts, Jag1a acts to maintain gene expression in HE and support transition to HSPC fate. Jag1a activity depends on blood flow-induced shear stress and rescues HSPC loss caused by impaired flow. Thus, rather than playing opposing roles, Dll4 and Jag1a act sequentially and coordinately to drive the endothelial-to-hematopoietic transition and promote HSPC emergence.
- Open Access
Genetic depletion in zebrafish uncovers requirement for septins in haematopoiesis
Haematopoiesis and differentiation of immune cells from haematopoietic stem and progenitor cells (HSPCs) are essential to core aspects of health and disease. A key player in haematopoiesis and HSPC differentiation is the cytoskeleton, which governs cell division and lineage bias. Despite insights using mouse models, regulation of haematopoiesis by the septin cytoskeleton is mostly unknown. Septins are unconventional filament forming proteins best known for roles in cell division and host defence. To investigate septin-mediated host defence in vivo , we generated septin-deficient zebrafish models for infection with Mycobacterium marinum . Unexpectedly, septin-deficient larvae were protected from mycobacterial infection due to significantly increased macrophage numbers, reduced cell death, and enhanced inflammatory responses. Underlying this, we found that septin-deficient larvae produce significantly more HSPCs and show myeloid lineage bias, establishing a requirement for septins in haematopoiesis. In agreement with classical HSPC hierarchy, increased myeloid production in septin-deficient larvae is at the expense of erythroid lineage production. Our findings that septins play a role in haematopoiesis is consistent with hallmarks of haematological disorders in which septin dysfunction has been implicated, including acute myeloid leukaemia, myelodysplastic syndrome, and platelet disorder Bernard-Soulier syndrome. These results highlight zebrafish as a new model to investigate septin-mediated haematopoiesis and application of septin-based medicines to treat blood disorders.
Open AccessGenetic depletion in zebrafish uncovers requirement for septins in haematopoiesis
Haematopoiesis and differentiation of immune cells from haematopoietic stem and progenitor cells (HSPCs) are essential to core aspects of health and disease. A key player in haematopoiesis and HSPC differentiation is the cytoskeleton, which governs cell division and lineage bias. Despite insights using mouse models, regulation of haematopoiesis by the septin cytoskeleton is mostly unknown. Septins are unconventional filament forming proteins best known for roles in cell division and host defence. To investigate septin-mediated host defence in vivo , we generated septin-deficient zebrafish models for infection with Mycobacterium marinum . Unexpectedly, septin-deficient larvae were protected from mycobacterial infection due to significantly increased macrophage numbers, reduced cell death, and enhanced inflammatory responses. Underlying this, we found that septin-deficient larvae produce significantly more HSPCs and show myeloid lineage bias, establishing a requirement for septins in haematopoiesis. In agreement with classical HSPC hierarchy, increased myeloid production in septin-deficient larvae is at the expense of erythroid lineage production. Our findings that septins play a role in haematopoiesis is consistent with hallmarks of haematological disorders in which septin dysfunction has been implicated, including acute myeloid leukaemia, myelodysplastic syndrome, and platelet disorder Bernard-Soulier syndrome. These results highlight zebrafish as a new model to investigate septin-mediated haematopoiesis and application of septin-based medicines to treat blood disorders.
- Open Access
- 26 January 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (4) , 831-833
Balancing act: how Apelin tunes vascular and haemogenic identities
Haematopoietic stem and progenitor cells (HSPCs) maintain haematopoiesis throughout life. Their formation occurs early in embryonic development and is regulated by many intrinsic and extrinsic factors that delicately balance the need to maintain a vascular network with the need to generate HSPCs de novo. Most extrinsic factors such as BMP and Notch act instructively in haemogenic endothelial cells to induce HSPC fates. A new study by Eberlein et al (2025) identifies a key role for Apelin signalling acting indirectly by limiting the number of arterial endothelial cells that become haemogenic, independently of Notch, BMP or Wnt signalling (Eberlein et al, 2025). Arterial endothelial cells that do not respond to Apelin more frequently convert to the haemogenic endothelial cell fate, giving rise to higher numbers of haematopoietic stem and progenitor cells in the embryo that persist into adulthood. This work highlights a critical temporal window where Apelin functions as a rheostat, balancing angiogenesis, vascular maintenance and haematopoiesis. New research in EMBO Reports identifies a function for Apelin signaling in balancing angiogenesis, vascular maintenance and haematopoiesis.
- 26 January 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (4) , 831-833
Open AccessBalancing act: how Apelin tunes vascular and haemogenic identities
Haematopoietic stem and progenitor cells (HSPCs) maintain haematopoiesis throughout life. Their formation occurs early in embryonic development and is regulated by many intrinsic and extrinsic factors that delicately balance the need to maintain a vascular network with the need to generate HSPCs de novo. Most extrinsic factors such as BMP and Notch act instructively in haemogenic endothelial cells to induce HSPC fates. A new study by Eberlein et al (2025) identifies a key role for Apelin signalling acting indirectly by limiting the number of arterial endothelial cells that become haemogenic, independently of Notch, BMP or Wnt signalling (Eberlein et al, 2025). Arterial endothelial cells that do not respond to Apelin more frequently convert to the haemogenic endothelial cell fate, giving rise to higher numbers of haematopoietic stem and progenitor cells in the embryo that persist into adulthood. This work highlights a critical temporal window where Apelin functions as a rheostat, balancing angiogenesis, vascular maintenance and haematopoiesis. New research in EMBO Reports identifies a function for Apelin signaling in balancing angiogenesis, vascular maintenance and haematopoiesis.
- Open Access
A dual readout embryonic zebrafish xenograft model of rhabdomyosarcoma to assess clinically relevant multi-receptor tyrosine kinase inhibitors
Background: Rhabdomyosarcoma (RMS) is a highly aggressive soft tissue sarcoma, affecting children and adolescents, with poor prognosis in some patient groups. Better therapeutic regimens and preclinical models to test them in are needed. Multi-receptor tyrosine kinase inhibitors (MRTKIs) are licensed for adult indications and explored in the clinic in sarcoma patients. The MRTKI Regorafenib is currently assessed in the relapse setting in patients with RMS ( NCT04625907 ). Reliable biomarkers of response for MRTKIs are lacking. MRTKIs act not only against the cancer cell, but also the supporting stroma, particularly the vasculature. The embryonic zebrafish is translucent and allows assessment of this interaction with high-throughput in vivo imaging. Methods: A new preclinical embryo zebrafish xenograft model was developed using Tg( flk1 :GFP) (blood vessel reporter) transgenic zebrafish embryos inoculated in the yolk with fluorescently labelled cells from 7 different RMS cell lines (fusion-positive (FP): Rh4, Rh30, Rh41, RMS-01, fusion-negative (FN): RD, JR1, SMS-CTR), and patient-derived cells IC-pPDX-104 at 50 hours post-fertilization and incubated at 34°C for up to 70 hours. Xenografts and vessel beds were imaged and analysed using custom FIJI pipelines. MRTKIs regorafenib and infigratinib were used at a concentration of 0.1uM added to the fish water 4 hours post cell inoculation. Pro-angiogenic growth factors VEFG-A, FGF-2 and PDGF-BB were measured in conditioned media of each cell line. Results: All 7 RMS cell lines and the patient-derived cells engrafted with tumour burden assessment by fluorescent imaging and direct cell counting indicating adequate growth and high cell viability during the observation period. RMS tumours induced neo-vascularisation towards the tumour and increased density of proximal vessel beds. MRTKI treatment revealed a greater tumour-intrinsic sensitivity of FP cells, but identified a significant blockade of neo-vascularisation across all RMS lines, with regorafenib response correlated with secretion of VEGF-A. Conclusion: We have developed an embryonic zebrafish xenograft model of RMS, which allows assessment of tumour growth, vascularisation initiation and therapeutic responses to clinically relevant MRTKIs. The identification of VEGF-A secretion as potential biomarker for Regorafenib response and the separation of therapeutic effects on tumour growth and neovascularisation suggests additional value of our model for response prediction to MRTKIs.
Open AccessA dual readout embryonic zebrafish xenograft model of rhabdomyosarcoma to assess clinically relevant multi-receptor tyrosine kinase inhibitors
Background: Rhabdomyosarcoma (RMS) is a highly aggressive soft tissue sarcoma, affecting children and adolescents, with poor prognosis in some patient groups. Better therapeutic regimens and preclinical models to test them in are needed. Multi-receptor tyrosine kinase inhibitors (MRTKIs) are licensed for adult indications and explored in the clinic in sarcoma patients. The MRTKI Regorafenib is currently assessed in the relapse setting in patients with RMS ( NCT04625907 ). Reliable biomarkers of response for MRTKIs are lacking. MRTKIs act not only against the cancer cell, but also the supporting stroma, particularly the vasculature. The embryonic zebrafish is translucent and allows assessment of this interaction with high-throughput in vivo imaging. Methods: A new preclinical embryo zebrafish xenograft model was developed using Tg( flk1 :GFP) (blood vessel reporter) transgenic zebrafish embryos inoculated in the yolk with fluorescently labelled cells from 7 different RMS cell lines (fusion-positive (FP): Rh4, Rh30, Rh41, RMS-01, fusion-negative (FN): RD, JR1, SMS-CTR), and patient-derived cells IC-pPDX-104 at 50 hours post-fertilization and incubated at 34°C for up to 70 hours. Xenografts and vessel beds were imaged and analysed using custom FIJI pipelines. MRTKIs regorafenib and infigratinib were used at a concentration of 0.1uM added to the fish water 4 hours post cell inoculation. Pro-angiogenic growth factors VEFG-A, FGF-2 and PDGF-BB were measured in conditioned media of each cell line. Results: All 7 RMS cell lines and the patient-derived cells engrafted with tumour burden assessment by fluorescent imaging and direct cell counting indicating adequate growth and high cell viability during the observation period. RMS tumours induced neo-vascularisation towards the tumour and increased density of proximal vessel beds. MRTKI treatment revealed a greater tumour-intrinsic sensitivity of FP cells, but identified a significant blockade of neo-vascularisation across all RMS lines, with regorafenib response correlated with secretion of VEGF-A. Conclusion: We have developed an embryonic zebrafish xenograft model of RMS, which allows assessment of tumour growth, vascularisation initiation and therapeutic responses to clinically relevant MRTKIs. The identification of VEGF-A secretion as potential biomarker for Regorafenib response and the separation of therapeutic effects on tumour growth and neovascularisation suggests additional value of our model for response prediction to MRTKIs.
- Open Access
- 22 May 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-14
ADA2 regulates inflammation and hematopoietic stem cell emergence via the A2bR pathway in zebrafish
Deficiency of adenosine deaminase 2 (DADA2) is an inborn error of immunity caused by loss-of-function mutations in the adenosine deaminase 2 (ADA2) gene. Clinical manifestations of DADA2 include vasculopathy and immuno-hematological abnormalities, culminating in bone marrow failure. A major gap exists in our knowledge of the regulatory functions of ADA2 during inflammation and hematopoiesis, mainly due to the absence of an ADA2 orthologue in rodents. Exploring these mechanisms is essential for understanding disease pathology and developing new treatments. Zebrafish possess two ADA2 orthologues, cecr1a and cecr1b, with the latter showing functional conservation with human ADA2. We establish a cecr1b-loss-of-function zebrafish model that recapitulates the immuno-hematological and vascular manifestations observed in humans. Loss of Cecr1b disrupts hematopoietic stem cell specification, resulting in defective hematopoiesis. This defect is caused by induced inflammation in the vascular endothelium. Blocking inflammation, pharmacological modulation of the A2r pathway, or the administration of the recombinant human ADA2 corrects these defects, providing insights into the mechanistic link between ADA2 deficiency, inflammation and immuno-hematological abnormalities. Our findings open up potential therapeutic avenues for DADA2 patients.
- 22 May 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-14
Open AccessADA2 regulates inflammation and hematopoietic stem cell emergence via the A2bR pathway in zebrafish
Deficiency of adenosine deaminase 2 (DADA2) is an inborn error of immunity caused by loss-of-function mutations in the adenosine deaminase 2 (ADA2) gene. Clinical manifestations of DADA2 include vasculopathy and immuno-hematological abnormalities, culminating in bone marrow failure. A major gap exists in our knowledge of the regulatory functions of ADA2 during inflammation and hematopoiesis, mainly due to the absence of an ADA2 orthologue in rodents. Exploring these mechanisms is essential for understanding disease pathology and developing new treatments. Zebrafish possess two ADA2 orthologues, cecr1a and cecr1b, with the latter showing functional conservation with human ADA2. We establish a cecr1b-loss-of-function zebrafish model that recapitulates the immuno-hematological and vascular manifestations observed in humans. Loss of Cecr1b disrupts hematopoietic stem cell specification, resulting in defective hematopoiesis. This defect is caused by induced inflammation in the vascular endothelium. Blocking inflammation, pharmacological modulation of the A2r pathway, or the administration of the recombinant human ADA2 corrects these defects, providing insights into the mechanistic link between ADA2 deficiency, inflammation and immuno-hematological abnormalities. Our findings open up potential therapeutic avenues for DADA2 patients.
- Open Access
- 22 January 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102810
Protocol for the analysis of hematopoietic lineages in the whole kidney marrow of adult zebrafish
- 22 January 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102810
Open AccessProtocol for the analysis of hematopoietic lineages in the whole kidney marrow of adult zebrafish
- Open Access
- 31 May 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (6) , 112571
Lineage skewing and genome instability underlie marrow failure in a zebrafish model of GATA2 deficiency
- 31 May 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (6) , 112571
Open AccessLineage skewing and genome instability underlie marrow failure in a zebrafish model of GATA2 deficiency
- Open Access
- 14 March 2022
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 50 (2) , 703-712
In the spotlight: the role of TGFβ signalling in haematopoietic stem and progenitor cell emergence
Haematopoietic stem and progenitor cells (HSPCs) sustain haematopoiesis by generating precise numbers of mature blood cells throughout the lifetime of an individual. In vertebrates, HSPCs arise during embryonic development from a specialised endothelial cell population, the haemogenic endothelium (HE). Signalling by the Transforming Growth Factor β (TGFβ) pathway is key to regulate haematopoiesis in the adult bone marrow, but evidence for a role in the formation of HSPCs has only recently started to emerge. In this review, we examine recent work in various model systems that demonstrate a key role for TGFβ signalling in HSPC emergence from the HE. The current evidence underpins two seemingly contradictory views of TGFβ function: as a negative regulator of HSPCs by limiting haematopoietic output from HE, and as a positive regulator, by programming the HE towards the haematopoietic fate. Understanding how to modulate the requirement for TGFβ signalling in HSC emergence may have critical implications for the generation of these cells in vitro for therapeutic use.
- 14 March 2022
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 50 (2) , 703-712
Open AccessIn the spotlight: the role of TGFβ signalling in haematopoietic stem and progenitor cell emergence
Haematopoietic stem and progenitor cells (HSPCs) sustain haematopoiesis by generating precise numbers of mature blood cells throughout the lifetime of an individual. In vertebrates, HSPCs arise during embryonic development from a specialised endothelial cell population, the haemogenic endothelium (HE). Signalling by the Transforming Growth Factor β (TGFβ) pathway is key to regulate haematopoiesis in the adult bone marrow, but evidence for a role in the formation of HSPCs has only recently started to emerge. In this review, we examine recent work in various model systems that demonstrate a key role for TGFβ signalling in HSPC emergence from the HE. The current evidence underpins two seemingly contradictory views of TGFβ function: as a negative regulator of HSPCs by limiting haematopoietic output from HE, and as a positive regulator, by programming the HE towards the haematopoietic fate. Understanding how to modulate the requirement for TGFβ signalling in HSC emergence may have critical implications for the generation of these cells in vitro for therapeutic use.
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Lineage Skewing and Genome Instability Underlie Marrow Failure in a Zebrafish Model of GATA2 Deficiency
Inherited bone marrow failure associated with heterozygous mutations in GATA2 predisposes towards haematological malignancies, but the mechanisms remain poorly understood . Here, we investigate the mechanistic basis of marrow failure in a zebrafish model of GATA2 deficiency. Single cell transcriptomics and chromatin accessibility assays reveal that loss of gata2a lead to skewing towards the erythroid lineage at the expense of myeloid cells, associated with loss of cebpa expression and decreased PU.1 and CEBPA transcription factor accessibility in Haematopoietic Stem and Progenitor cells (HSPCs). Furthermore, gata2a mutants showed impaired expression of npm1a, the zebrafish NPM1 orthologue. Progressive loss of npm1a in HSPCs was associated with elevated levels of DNA damage and increased mutational burden in gata2a mutants. Thus, Gata2a maintains myeloid lineage priming through cebpa and protects against genome instability and marrow failure by maintaining expression of npm1a. Our results establish a potential mechanism underlying bone marrow failure in GATA2 deficiency.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessLineage Skewing and Genome Instability Underlie Marrow Failure in a Zebrafish Model of GATA2 Deficiency
Inherited bone marrow failure associated with heterozygous mutations in GATA2 predisposes towards haematological malignancies, but the mechanisms remain poorly understood . Here, we investigate the mechanistic basis of marrow failure in a zebrafish model of GATA2 deficiency. Single cell transcriptomics and chromatin accessibility assays reveal that loss of gata2a lead to skewing towards the erythroid lineage at the expense of myeloid cells, associated with loss of cebpa expression and decreased PU.1 and CEBPA transcription factor accessibility in Haematopoietic Stem and Progenitor cells (HSPCs). Furthermore, gata2a mutants showed impaired expression of npm1a, the zebrafish NPM1 orthologue. Progressive loss of npm1a in HSPCs was associated with elevated levels of DNA damage and increased mutational burden in gata2a mutants. Thus, Gata2a maintains myeloid lineage priming through cebpa and protects against genome instability and marrow failure by maintaining expression of npm1a. Our results establish a potential mechanism underlying bone marrow failure in GATA2 deficiency.
- Open Access
- 30 November 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (23) , 4935-4948
Hapln1b, a central organizer of the ECM, modulates kit signaling to control developmental hematopoiesis in zebrafish
During early vertebrate development, hematopoietic stem and progenitor cells (HSPCs) are produced in hemogenic endothelium located in the dorsal aorta, before they migrate to a transient niche where they expand to the fetal liver and the caudal hematopoietic tissue, in mammals and zebrafish, respectively. In zebrafish, previous studies have shown that the extracellular matrix (ECM) around the aorta must be degraded to enable HSPCs to leave the aortic floor and reach blood circulation. However, the role of the ECM components in HSPC specification has never been addressed. In this study, hapln1b, a key component of the ECM, was specifically expressed in hematopoietic sites in the zebrafish embryo. Gain- and loss-of-function experiments all resulted in the absence of HSPCs in the early embryo, showing that hapln1b is necessary, at the correct level, to specify HSPCs in the hemogenic endothelium. Furthermore, the expression of hapln1b was necessary to maintain the integrity of the ECM through its link domain. By combining functional analyses and computer modeling, we showed that kitlgb interacts with the ECM to specify HSPCs. The findings show that the ECM is an integral component of the microenvironment and mediates the cytokine signaling that is necessary for HSPC specification.
- 30 November 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (23) , 4935-4948
Open AccessHapln1b, a central organizer of the ECM, modulates kit signaling to control developmental hematopoiesis in zebrafish
During early vertebrate development, hematopoietic stem and progenitor cells (HSPCs) are produced in hemogenic endothelium located in the dorsal aorta, before they migrate to a transient niche where they expand to the fetal liver and the caudal hematopoietic tissue, in mammals and zebrafish, respectively. In zebrafish, previous studies have shown that the extracellular matrix (ECM) around the aorta must be degraded to enable HSPCs to leave the aortic floor and reach blood circulation. However, the role of the ECM components in HSPC specification has never been addressed. In this study, hapln1b, a key component of the ECM, was specifically expressed in hematopoietic sites in the zebrafish embryo. Gain- and loss-of-function experiments all resulted in the absence of HSPCs in the early embryo, showing that hapln1b is necessary, at the correct level, to specify HSPCs in the hemogenic endothelium. Furthermore, the expression of hapln1b was necessary to maintain the integrity of the ECM through its link domain. By combining functional analyses and computer modeling, we showed that kitlgb interacts with the ECM to specify HSPCs. The findings show that the ECM is an integral component of the microenvironment and mediates the cytokine signaling that is necessary for HSPC specification.